相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Phase I studies of AVE9633, an anti-CD33 antibody-maytansinoid conjugate, in adult patients with relapsed/refractory acute myeloid leukemia
Simona Lapusan et al.
INVESTIGATIONAL NEW DRUGS (2012)
Acute myeloid leukaemia in the elderly: a review
Daniel A. Pollyea et al.
BRITISH JOURNAL OF HAEMATOLOGY (2011)
SAR3419: An Anti-CD19-Maytansinoid Immunoconjugate for the Treatment of B-Cell Malignancies
Veronique Blanc et al.
CLINICAL CANCER RESEARCH (2011)
Antibody-Drug Conjugates of Calicheamicin Derivative: Gemtuzumab Ozogamicin and Inotuzumab Ozogamicin
Alejandro D. Ricart
CLINICAL CANCER RESEARCH (2011)
Bispecific antibodies engage T cells for antitumor immunotherapy
Bryan D. Choi et al.
EXPERT OPINION ON BIOLOGICAL THERAPY (2011)
High CD33 expression levels in acute myeloid leukemia cells carrying the nucleophosmin (NPM1) mutation
Maria Stefania De Propris et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2011)
Therapeutic Advances in Acute Myeloid Leukemia
Alan Burnett et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Complete remission after blinatumomab-induced donor T-cell activation in three pediatric patients with post-transplant relapsed acute lymphoblastic leukemia
R. Handgretinger et al.
LEUKEMIA (2011)
Simultaneous engagement of the activatory receptors NKG2D and CD3 for retargeting of effector cells to CD33-positive malignant cells
S. Stamova et al.
LEUKEMIA (2011)
A single-chain triplebody with specificity for CD19 and CD33 mediates effective lysis of mixed lineage leukemia cells by dual targeting
Ingo Schubert et al.
MABS (2011)
Program death-1 signaling and regulatory T cells collaborate to resist the function of adoptively transferred cytotoxic T lymphocytes in advanced acute myeloid leukemia
Qing Zhou et al.
BLOOD (2010)
A recombinant trispecific single-chain Fv derivative directed against CD123 and CD33 mediates effective elimination of acute myeloid leukaemia cells by dual targeting
Markus Kuegler et al.
BRITISH JOURNAL OF HAEMATOLOGY (2010)
Epitope distance to the target cell membrane and antigen size determine the potency of T cell-mediated lysis by BiTE antibodies specific for a large melanoma surface antigen
Claudia Bluemel et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2010)
Impaired antigen presentation in neoplasia: basic mechanisms and implications for acute myeloid leukemia
Marvin M. van Luijn et al.
IMMUNOTHERAPY (2010)
Effective Elimination of Acute Myeloid Leukemic Cells by Recombinant Bispecific Antibody Derivatives Directed Against CD33 and CD16
Heiko Singer et al.
JOURNAL OF IMMUNOTHERAPY (2010)
T cell-engaging BiTE antibodies specific for EGFR potently eliminate KRAS- and BRAF-mutated colorectal cancer cells
Ralf Lutterbuese et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2010)
Peripheral blood T cells in acute myeloid leukemia (AML) patients at diagnosis have abnormal phenotype and genotype and form defective immune synapses with AML blasts
Rifca Le Dieu et al.
BLOOD (2009)
Correlation between flow cytometric identification of CD33-positive cells and morphological evaluation of myeloblasts in bone marrow of patients with acute myeloblastic leukemia
Satoko Oka et al.
HEMATOLOGY (2009)
Mode of cytotoxic action of T cell-engaging BiTE antibody MT110
Cornelia Haas et al.
IMMUNOBIOLOGY (2009)
Age-Related Risk Profile and Chemotherapy Dose Response in Acute Myeloid Leukemia: A Study by the German Acute Myeloid Leukemia Cooperative Group
Thomas Buechner et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
In situ analysis of the antigen-processing machinery in acute myeloid leukaemic blasts by tissue microarray
S. Hoves et al.
LEUKEMIA (2009)
A Novel CD19-directed Recombinant Bispecific Antibody Derivative With Enhanced Immune Effector Functions for Human Leukemic Cells
Christian Kellner et al.
JOURNAL OF IMMUNOTHERAPY (2008)
Tumor regression in cancer patients by very low doses of a T cell-engaging antibody
Ralf Bargou et al.
SCIENCE (2008)
Strictly target cell-dependent activation of T cells by bispecific single-chain antibody constructs of the BiTE class
Klaus Brischwein et al.
JOURNAL OF IMMUNOTHERAPY (2007)
CD19/CD3-bispecific antibody of the BiTE class is far superior to tandem diabody with respect to redirected tumor cell lysis
Michael Molhoj et al.
MOLECULAR IMMUNOLOGY (2007)
Expression of the target receptor CD33 in CD34(+)/CD38(-)/CD123(+) AML stem cells
A. W. Hauswirth et al.
EUROPEAN JOURNAL OF CLINICAL INVESTIGATION (2007)
Circulating T cells in patients with untreated acute myelogenous leukemia are heterogeneous and can be activated through the CD3/TCR complex
Elisabeth Ersvaer et al.
HEMATOLOGY (2007)
Hematopoietic stem cells express multiple myeloid markers: implications for the origin and targeted therapy of acute myeloid leukemia
DC Taussig et al.
BLOOD (2005)
Phase III randomized multicenter study of a humanized anti-CD33 monoclonal antibody, lintuzumab, in combination with chemotherapy, versus chemotherapy alone in patients with refractory or first-relapsed acute myeloid leukemia
EJ Feldman et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Influence of CD33 expression levels and ITIM-dependent internalization on gemtuzumab ozogamicin-induced cytotoxicity
RB Walter et al.
BLOOD (2005)
Functional characterization of T lymphocytes derived from patients with acute myelogenous leukemia and chemotherapy-induced leukopenia
O Wendelbo et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2004)
Inhibition of acute myeloid leukemia cell growth by mono-specific and bi-specific anti-CD33 x anti-CD64 antibodies
L Balaian et al.
LEUKEMIA RESEARCH (2004)
Monocyte enrichment from leukapharesis products for the generation of DCs by plastic adherence, or by positive or negative selection
T Felzmann et al.
CYTOTHERAPY (2003)
Differences in CD33 intensity between various myeloid neoplasms
I Jilani et al.
AMERICAN JOURNAL OF CLINICAL PATHOLOGY (2002)
分享论文
